Login / Signup

Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges.

Xabier Mielgo-RubioMargarita MartínJordi RemonOliver HigueraVirginia CalvoJosé Ramón JaraboEsther CondeJavier LunaMariano Provencio PullaJavier De Castro CarpeñoFernando López-RíosFlorentino Hernando TranchoFelipe Couñago
Published in: Future oncology (London, England) (2021)
Lung cancer continues to be the leading cause of cancer mortality and a serious health problem despite the numerous advances made in the last decade and the rapid advance of research in this field. In recent years, there has been a decrease in mortality from lung cancer coinciding with the approval times of targeted therapy. To date, targeted therapy has been used in the context of advanced disease in clinical practice, with great benefits in survival and quality of life. The next step will be to incorporate targeted therapy into the treatment of earlier stages of non-small-cell lung cancer, and there is already a randomized trial showing a disease-free survival benefit. However, there are many questions that need to be resolved first. In the present review, the authors discuss the findings of published reports and ongoing clinical trials assessing the role of targeted therapies in nonmetastatic disease.
Keyphrases